2023年6月最新SCI影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CLINICAL CANCER RESEARCH CLIN CANCER RES （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.3
51人评分
我要评分
声誉 9.9 影响力 8.7 速度 9.6 | |||||||||||||||||
| 期刊ISSN | 1078-0432 | 微信扫码收藏此期刊 | ||||||||||||||||
| E-ISSN | 1557-3265 | |||||||||||||||||
| 2022-2023最新影响因子 （数据来源于搜索引擎） | 11.5 点击查看影响因子趋势图 | |||||||||||||||||
| 实时影响因子 | 截止2023年9月27日：6.552 | |||||||||||||||||
| 2022-2023自引率 | 1.70%点击查看自引率趋势图 | |||||||||||||||||
| 五年影响因子 | 12.5 | |||||||||||||||||
| h-index | 292 | |||||||||||||||||
| CiteScore |
| |||||||||||||||||
| 期刊简介 | Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease. Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease. | |||||||||||||||||
| 期刊官方网站 | http://clincancerres.aacrjournals.org/ | |||||||||||||||||
| 期刊投稿网址 | http://ccr.msubmit.net/cgi-bin/main.plex | |||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足CLINICAL CANCER RESEARCH的语言要求，还能让CLINICAL CANCER RESEARCH编辑和审稿人得到更好的审稿体验，让稿件最大限度地被CLINICAL CANCER RESEARCH编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||
| 通讯方式 | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 | |||||||||||||||||
| 出版商 | American Association for Cancer Research Inc. | |||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||
| 出版语言 | English | |||||||||||||||||
| 出版周期 | Semimonthly | |||||||||||||||||
| 出版年份 | 1995 | |||||||||||||||||
| 年文章数 | 491点击查看年文章数趋势图 | |||||||||||||||||
| Gold OA文章占比 | 18.13% | |||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 93.69% | |||||||||||||||||
| WOS期刊SCI分区 （ 2022-2023年最新版） | WOS分区等级：1区
| |||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1078-0432%5BISSN%5D | |||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2.1月 | |||||||||||||||||
| 平均录用比例 | 网友分享经验： 约30% | |||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在CLINICAL CANCER RESEARCH顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy Author: Chen, Wei; Shi, Hui; Liu, Zhuojun; Yang, Fan; Liu, Jia; Zhang, Leqiang; Wu, Yajin; Xia, Yuanshi; Ou, Yuxuan; Li, Ruiting; Zhang, Ting; Zhang, Jiecheng; Ke, Xiaoyan; Hu, Kai; Yu, Jian Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 8, pp. 1484-1495. DOI: 10.1158/1078-0432.CCR-22-2924 PubMed DOI |
| 2. | Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies Author: Zhai, Yifan; Tang, Qiuqiong; Fang, Douglas D.; Deng, Jing; Zhang, Kaixiang; Wang, Qixin; Yin, Yan; Fu, Chengcheng; Xue, Sheng -Li; Li, Na; Zhou, Feng; Yang, Dajun Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 183-196. DOI: 10.1158/1078-0432.CCR-22-0978 PubMed DOI |
| 3. | Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer Author: Peng, Ke; Zhang, Feifei; Wang, Yichen; Sahgal, Pranshu; Li, Tianxia; Zhou, Jin; Liang, Xiaoyan; Zhang, Yanxi; Sethi, Nilay; Liu, Tianshu; Zhang, Haisheng; Bass, Adam J. Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 197-208. DOI: 10.1158/1078-0432.CCR-22-1609 PubMed DOI |
| 4. | Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes Author: Bai, Jiwei; Shi, Jianxin; Zhang, Yazhuo; Li, Chuzhong; Xiong, Yujia; Koka, Hela; Wang, Difei; Zhang, Tongwu; Song, Lei; Luo, Wen; Zhu, Bin; Hicks, Belynda; Hutchinson, Amy; Kirk, Erin; Troester, Melissa A.; Li, Mingxuan; Shen, Yutao; Ma, Tianshun; Wang, Junmei; Liu, Xing; Wang, Shuai; Gui, Songbai; McMaster, Mary L.; Chanock, Stephen J.; Parry, Dilys M.; Goldstein, Alisa M.; Yang, Xiaohong R. Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 261-270. DOI: 10.1158/1078-0432.CCR-22-1865 PubMed DOI |
| 5. | Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma Author: Wang, Jun; Guo, Wei; Wang, Xiaofang; Tang, Xiaodong; Sun, Xin; Ren, Tingting Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 3, pp. 659-666. DOI: 10.1158/1078-0432.CCR-22-2682 PubMed DOI |
| 6. | Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Author: Luo, Ren; Onyshchenko, Kateryna; Wang, Liqun; Gaedicke, Simone; Grosu, Anca-Ligia; Firat, Elke; Niedermann, Gabriele Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 3, pp. 667-683. DOI: 10.1158/1078-0432.CCR-22-1591 PubMed DOI |
| 7. | First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001 Author: Zhou, Yan; Yang, Qingcheng; Dong, Yang; Ji, Tong; Zhang, Bing; Yang, Cheng; Zheng, Shuier; Tang, Lina; Zhou, Chenliang; Qian, Guowei; Huang, Yujing; Yu, Wenxi; Li, Hongtao; Wang, Yonggang; He, Aina; Shen, Zan; Bao, Qiyuan; Hua, Yingqi; Bai, Hongyu; Zhao, Jiayi; Li, Xiaoyi; Dai, Xiangrong; Zhang, Jianjun; Hu, Haiyan; Yao, Yang Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 764-774. DOI: 10.1158/1078-0432.CCR-22-2470 PubMed DOI |
| 8. | Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma Author: Song, Xuyang; Kelley, Robin Kate; Khan, Anis A.; Standifer, Nathan; Zhou, Diansong; Lim, KyoungSoo; Krishna, Rajesh; Liu, Lu; Wang, Kun; McCoon, Patricia; Negro, Alejandra; He, Philip; Gibbs, Megan; Kurland, John F.; Abou-Alfa, Ghassan K. Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 754-763. DOI: 10.1158/1078-0432.CCR-22-1983 PubMed DOI |
| 9. | Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer Author: Chen, Huang; Zhou, Wenbo; Bian, Aiwu; Zhang, Qiansen; Miao, Ying; Yin, Xuan; Ye, Jiangnan; Xu, Shifen; Ti, Chaowen; Sun, Zhenliang; Zheng, Jianghua; Chen, Yihua; Liu, Mingyao; Yi, Zhengfang Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 815-830. DOI: 10.1158/1078-0432.CCR-22-0997 PubMed DOI |
| 10. | An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas Author: Lu, Xiaofan; Vano, Yann; Helleux, Alexandra; Su, Xiaoping; Lindner, Veronique; Davidson, Guillaume; Mouawad, Roger; Spano, Jean-Philippe; Roupre, Morgan; Elaidi, Reza; Comperat, Eva; Verkarre, Virginie; Sun, Chengming; Chevreau, Christine; Bennamoun, Mostefa; Lang, Herve; Tricard, Thibault; Cheng, Wenxuan; Xu, Li; Davidson, Irwin; Yan, Fangrong; Fridman, Wolf Herman; Sautes-Fridman, Catherine; Oudard, Stephane; Malouf, Gabriel G. Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 7, pp. 1279-1291. DOI: 10.1158/1078-0432.CCR-22-2133 PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共6条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
